The Sonire Therapeutics ultrasound system is currently being studied for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to first-line chemotherapy.
The Food and Drug Administration (FDA) has issued a breakthrough device designation to Sonire Therapeutics for the use of its high-intensity focused ultrasound (HIFU) system (Suizenji) to treat pancreatic cancer, a disease that may claim the lives of 51,750 people in the United States in 2024, according to estimates from the American Cancer Society.1,2
Through the use of cavitation ultrasound, Sonire Therapeutics said the Suizenji HIFU system facilitates the delivery of thermal therapy with lower acoustic energy in addition to providing image clarity for targeted treatment.3
The high-intensity focused ultrasound (HIFU) system Suizenji (Sonire Therapeutics) has garnered the FDA's breakthrough device designation for pancreatic cancer treatment. The HIFU system is currently being evaluated in a phase 2 trial for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to initial chemotherapy. (Image courtesy of Sonire Therapeutics.)
“These are key features to achieve both safety and treatment throughput in our system,” noted Tohru Satoh, the chief executive officer of Sonire Therapeutics, in a 2023 interview.3
Researchers are currently comparing adjunctive use of the emerging HIFU system with second-line chemotherapy versus chemotherapy alone in a phase 2 trial for the treatment of patients with unresectable pancreatic cancer refractory or intolerant to initial chemotherapy, according to Sonire Therapeutics.
References
1. Sonire Therapeutics. Sonire’s HIFU therapy system designated as breakthrough device by FDA. PR Newswire. Available at: https://www.prnewswire.com/news-releases/sonires-hifu-therapy-system-designated-as-breakthrough-device-by-fda-302277187.html . Published October 16, 2024. Accessed October 16, 2024.
2. American Cancer Society. Key statistics for pancreatic cancer. Available at: https://www.cancer.org/cancer/types/pancreatic-cancer/about/key-statistics.html#:~:text=The%20average%20lifetime%20risk%20of,Cancer%20Survival%20Rates%20by%20Stage. . Accessed October 16, 2024.
3. Focused Ultrasound Foundation. Company profile: Sonfire Therapeutics. Available at: https://www.fusfoundation.org/posts/company-profile-sonire-therapeutics/#:~:text=We%20spoke%20with%20the%20SONIRE's,what%20makes%20their%20device%20unique. . Published February 22, 2023. Accessed October 16, 2024.
Possible Real-Time Adaptive Approach to Breast MRI Suggests ‘New Era’ of AI-Directed MRI
June 3rd 2025Assessing the simulated use of AI-generated suspicion scores for determining whether one should continue with full MRI or shift to an abbreviated MRI, the authors of a new study noted comparable sensitivity, specificity, and positive predictive value for biopsies between the MRI approaches.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Large Study Affirms Safety of Ultrasound Enhancing Agents for Echocardiography
May 16th 2025Those receiving ultrasound enhancing agents (UEAs) for transthoracic or stress echocardiography had lower odds of all-cause death in comparison to patients who did not have UEAs, according to a nationwide study involving 11.4 million patients.
BrightHeart Garners Third FDA Clearance for AI-Powered Assessments of Fetal Heart Ultrasound
May 14th 2025The latest FDA 510(k) clearance is for B-Right Views, an AI-enabled device, which provides automated detection of required views necessary for second- and third-trimester fetal heart ultrasound exams.